SAN DIEGO—(BUSINESS WIRE)—April 20, 2007—ACADIA PharmaceuticalsInc. (Nasdaq:ACAD) announced today that the underwriters haveexercised in full their over-allotment option to purchase 862,500shares of the Company's common stock, in connection with its publicoffering that priced on April 4, 2007. Including the over-allotmentshares being purchased, the offering totaled 6,612,500 shares at apublic offering price of $15.50 per share, resulting in aggregate netproceeds to ACADIA of approximately $96.1 million after deductingunderwriting discounts and commissions and estimated offeringexpenses.
The book-running managers for the offering are Banc of AmericaSecurities LLC and Lehman Brothers Inc., the co-lead manager isDeutsche Bank Securities Inc., and the co-managers are Piper Jaffray &Co., JMP Securities LLC and Rodman & Renshaw, LLC.
A registration statement relating to these securities was filedand has been declared effective by the Securities and ExchangeCommission. This press release shall not constitute an offer to sellor the solicitation of an offer to buy these securities, nor shallthere be any sale of these securities, in any jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior toregistration or qualification under the securities laws of any suchjurisdiction. The offering of these securities may be made only bymeans of the prospectus supplement, related prospectus and anysupplemental information relating to the offering. You may obtaincopies of the prospectus supplement and related prospectus bycontacting Banc of America Securities LLC, Capital Markets (ProspectusFulfillment) by e-mail todg.prospectus_distribution@bofasecurities.com or by mail to Banc ofAmerica Securities LLC, Capital Markets Operations, 100 West 33rdStreet, 3rd Floor, New York, NY 10001 and Lehman Brothers Inc. bye-mail to qiana.smith@broadridge.com or by fax to (631) 254-7268 or bymail to Lehman Brothers, c/o Qiana Smith, Broadridge, ProspectusFulfillment, 1155 Long Island Avenue, Edgewood, NY 11717.
ACADIA Pharmaceuticals is a biopharmaceutical company with itscorporate headquarters located in San Diego, California and researchand development operations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and
Chief Financial Officer
858-558-2871